This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
… with the idea to hijack the endogenous RNA editing enzyme ‘ADAR’ in our cells and to redirect it to any target of … oligonucleotides that will go in to a cell and attract the ADAR enzymes to a particular site on the RNA that they want …
